Ebola Virus Disease
📧 Sign up to get email alerts when something new happens for Ebola Virus Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-14Clinical Trial Results: Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola [Phase 2]
Phase 2 trial assessing immunogenicity and safety of a heterologous Ebola vaccine regimen; results posted after completion.
-
CLINICAL_TRIALS research · 2026-06-17Clinical Trial Results: Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP Vaccine) [Phase 2]
Phase 2 trial results assessing the immunogenicity of the rVSV∆G-ZEBOV-GP Ebola vaccine in healthy volunteers.
-
EMA guidance · 2026-06-15EMA Management Board: highlights of June 2026 meeting
EMA Management Board highlights June 2026 include support to EU Ebola outbreak response and a positive assessment of the 2025 annual activit…
-
EMA guidance · 2026-06-03EMA, AMA and African regulatory authorities join forces on Ebola outbreak response
Regulatory authorities from EMA, AMA, and African partners announce collaboration to respond to Ebola outbreaks, including discussions on cl…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia
This completed clinical trial study reports on long-term neurologic and neurocognitive sequelae in pediatric Ebola survivors in Liberia.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers
A completed clinical trial update tracking the durability of vaccine-induced immunity against Ebola in healthcare workers who were previousl…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein [Phase 1]
A Phase 1 clinical trial of a live-attenuated HPIV3 vectored vaccine expressing Ebola Zaire glycoprotein has been terminated; the Ebola Viru…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers [Phase 2]
Phase 2 clinical trial examining whether delaying Inmazeb (REGN-EB3) administration relative to Ervebo vaccination alters Ebola vaccine immu…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Immunology of Ebola Vaccine [Phase 2]
An update on a Phase 2 immunology study of an Ebola vaccine sponsored by Emory University; the trial is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: EBOla Post-Exposure Prophylaxis [Phase 3]
A Phase 3 trial evaluating post-exposure prophylaxis for Ebola virus disease is not yet recruiting.
-
EMA approval · 2026-01-16EMA Authorised: Ervebo (recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Ervebo for vaccination against Ebola virus disease, using a recombinant vesicular stomatitis virus …
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: REVIVE (Response to the Ebola Virus Vaccine) [Phase 4]
This document provides an update on a Phase 4 clinical trial (REVIVE) evaluating a response to an Ebola virus vaccine sponsored by Tulane Un…
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z [Phase 1]
The Phase I trial evaluating the Ebola vaccines cAd3-EBO Z and MVA-EBO Z conducted by the University of Oxford has been terminated.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
This document describes an Expanded Access Protocol for REGN-EB3 to treat Ebola Virus Disease. The protocol is currently available.
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Efficacy of Favipiravir Against Ebola (JIKI) [Phase 2]
Phase 2 trial (JIKI) evaluating Favipiravir for Ebola virus disease has completed; the update summarizes the efficacy findings.
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)
A completed clinical trial update from INSERM evaluating and providing support to Ebola virus disease survivors and their contacts.
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers [Phase 1]
This update reports the completion of a Phase 1 safety trial evaluating MVA-BN Filo and Ad26.ZEBOV vaccines in healthy volunteers.
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
This clinical trial update summarizes the natural history, disease progression, and long-term neurologic sequelae observed in Ebola virus di…
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure [Phase 2]
Phase 2 study assessing the immunogenicity of the rVSV-ZEBOV-GP Ebola vaccine for pre-exposure prophylaxis in individuals at potential occup…
-
CLINICAL_TRIALS trial_result · 2025-06-22Clinical Trial Update: A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants [Phase 3]
Phase 3 study evaluating the immunogenicity, safety and tolerability of the Ebola vaccine regimen Ad26.ZEBOV prime followed by MVA-BN-Filo b…
-
EMA approval · 2025-05-14EMA Authorised: Zabdeno (recombinant adenovirus type 26 (Ad26) encoding the glycoprotein (GP) of the Ebola virus Zaire (ZEBOV) Mayinga strain) — Janssen-Cilag International N.V.
The EMA authorised Zabdeno, a recombinant Ad26 Ebola vaccine by Janssen-Cilag International N.V., for prevention of Ebola virus disease.
-
EMA approval · 2025-05-14EMA Authorised: Mvabea (recombinant Modified Vaccinia Ankara Bavarian Nordic Virus encoding the: Ebola virus Zaire (ZEBOV) Mayinga strain glycoprotein (GP); Ebola virus Sudan Gulu strain GP; Ebola virus Taï Forest strain nucleoprotein and the Marburg virus Musoke strain GP) — Janssen-Cilag International N.V.
EMA authorised Mvabea, a recombinant Modified Vaccinia Ankara-based vaccine developed by Janssen-Cilag International N.V., for prevention of…
-
CLINICAL_TRIALS trial_result · 2025-05-11Clinical Trial Update: Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study [Phase 2]
Phase 2 clinical trial update evaluating Ad26.ZEBOV and MVA-BN-Filo vaccines in children and adults previously vaccinated in the EBOVAC-Salo…
-
CLINICAL_TRIALS research · 2025-04-24Clinical Trial Update: Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure [Phase 3]
This clinical trial update concerns the VSV-EBOV Ebola vaccine. It includes assessment of a booster dose in individuals at potential occupat…
-
CLINICAL_TRIALS research · 2025-03-18Clinical Trial Update: Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC [Phase 3]
Phase 3 trial evaluating safety and immunogenicity of Ervebo and Zabdeno booster vaccines against Ebola virus in people previously vaccinate…